Abstract
Background. A 33-year-old man was referred to a specialist center with a left neck mass and hypertension. The patient underwent surgery, which confirmed a malignant neck paraganglioma with metastasis to a cervical lymph node. He had no family history of carotid body tumors or pheochromocytoma.
Investigations. Measurements of plasma free metanephrines and chromogranin A; radiographic evaluations with CT, 18F-fluorodeoxyglucose PET and 123I-labeled metaiodobenzylguanidine scan; gene analysis for mutations in the SDHD and the KIT gene.
Diagnosis. Paraganglioma syndrome type 1 in a patient with a paraganglioma, bilateral pheochromocytomas and a gastrointestinal stromal tumor with a somatic Asp579del KIT mutation.
Management. The patient underwent surgical excision of all tumors after adequate preparation with alpha and beta blockers. Blood pressure normalized after surgery. The patient is examined regularly with biochemical and radiographic studies, and his follow-up is expected to last throughout life.
References
Carney, J. A. & Stratakis, C. A. Familial paraganglioma and gastric stromal sarcoma: a new syndrome distinct from the Carney Triad. Am. J. Med. Genet. 108, 132–139 (2002).
Brink, I., Hoegerle, S., Klisch, J. & Bley, T. A. Imaging of pheochromocytoma and paraganglioma, Fam. Cancer 4, 61–68 (2005).
Pacak, K. et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat. Clin. Pract Endocrinol. Metab. 3, 92–102 (2007).
Juweid, M. E. & Cheson, B. D. Positron-emission tomography and assessment of cancer therapy. N. Engl. J. Med. 354, 496–507 (2006).
Havekes, B. et al. Detection and treatment of pheochromocytomas and paragangliomas: current standing of MIBG scintigraphy and future role of PET imaging. Q. J. Nucl. Med. Mol. Imaging 52, 419–429 (2008).
Timmers, H. J. et al. Use of 6-[18F]-fluorodopamine positron emission tomography (PET) as first-line investigation for the diagnosis and localization of non-metastatic and metastatic pheochromocytoma (PHEO). Clin. Endocrinol. (Oxf.) 71, 11–17 (2009).
Timmers, H. J. et al. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J. Clin. Oncol. 25, 2262–2269 (2007).
Gayed, I. et al. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J. Nucl. Med. 45, 17–21 (2004).
Das, A., Wilson, R., Biankin, A. V. & Merrett, N. D. Surgical therapy for gastrointestinal stromal tumor of the upper gastrointestinal tract. J. Gastrointest. Surg. 13, 1220–1225 (2009).
Gimenez-Roqueplo, A. P. et al. Recent advances in the genetics of phaechromocytoma and functional paraganglioma. Clin. Exp. Pharmacol. Physiol. 35, 376–379 (2008).
Jimenez, C., Cote, G., Arnold, A. & Gagel, R. F. Review: should patients with apparently sporadic pheochromocytomas or paragangliomas be screened for hereditary syndromes? J. Clin. Endocrinol. Met. 91, 2851–2858 (2006).
Gimenez-Roqueplo, A. P. et al. The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway. Am. J. Hum. Genet. 69, 1186–1197 (2001).
Ishii, N. et al. A mutation in succinate dehydrogenase cytochrome b causes oxidative stress and ageing in nematodes. Nature 394, 694–697 (1998).
Hao, H. et al. SDH5, a gene required for flavination of succinate dehydrogenase is mutated in paraganglioma. Science 325, 1139–1142 (2009).
Baysal, B. E. Clinical and molecular progress in hereditary paraganglioma. J. Med. Genet. 45, 689–694 (2008).
Baysal, B. E. A recurrent stop-codon mutation in succinate dehydrogenase subunit B gene in normal peripheral blood and childhood T-cell acute leukemia. PLoS ONE 2, e436 (2007).
Benn, D. E. et al. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J. Clin. Endocrinol. Metab. 91, 827–836 (2006).
Hensen, E. et al. Somatic loss of maternal chromosome 11 causes parent-of-origin dependent in SDHD-linked paraganglioma and phaeochromocytoma families. Oncogene 23, 4076–4083 (2004).
Pigny, P. et al. Paraganglioma after maternal transmission of a succinate dehydrogenase gene mutation. J. Clin. Endocrinol. Metab. 93, 1609–1615 (2008).
Neumann, H. P. & Erlic, Z. Maternal transmission of symptomatic disease with SDHD mutation: fact or fiction? J. Clin. Endocrinol. Metab. 93, 1573–1575 (2008).
Van Nederveen, F. et al. An immunohistochemical procedure to detect patients with paraganglioma and pheochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol. 10, 764–771 (2009).
Astrom, K., Cohen, J. E., Willett-Brozick, J. E., Aston, C. E. & Baysal, B. Altitude is a phenotypic modifier in hereditary paraganglioma type 1: evidence for an oxygen-sensing defect. Hum. Genet. 113, 228–237 (2003).
Havekes, B. et al. Malignant paragangliomas associated with mutations in the succinate dehydrogenase D gene, J. Clin. Endocrinol. Metab. 92, 1245–1248 (2007).
Timmers, H. J. et al. Mutations associated with succinate dehydrogenase D-related malignant paragangliomas. Clin. Endocrinol. (Oxf.) 68, 561–566 (2008).
Lee, J. E., Curley, S. A., Gagel, R. F., Evans, D. B. & Hickey, R. C. Cortical-sparing adrenalectomy for patients with bilateral pheochromocytoma. Surgery, 120, 1064–1071 (1996).
Yip, L. et al. Surgical management of hereditary pheochromocytoma. J. Am. Coll. Surg. 198, 525–534 (2004).
Gross, D. J. et al. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocr. Relat. Cancer 13, 535–540 (2006).
Santarpia, L., Habra, M. A. & Jimenez, C. Malignant pheochromocytomas and paragangliomas: molecular signaling pathways and emerging therapies. Horm. Metab. Res. 41, 680–686 (2009).
Acknowledgements
Written consent for publication was obtained from the patient. M. Ayala-Ramirez and G. G. Callender contributed equally to this manuscript.
Désirée Lie, University of California, Orange, CA, is the author of and is solely responsible for the content of the learning objectives, questions and answers of the MedscapeCME-accredited continuing medical education activity associated with this article.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Ayala-Ramirez, M., Callender, G., Kupferman, M. et al. Paraganglioma syndrome type 1 in a patient with Carney–Stratakis syndrome. Nat Rev Endocrinol 6, 110–115 (2010). https://doi.org/10.1038/nrendo.2009.250
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2009.250
- Springer Nature Limited
This article is cited by
-
Succinate dehydrogenase deficiency in a PDGFRA mutated GIST
BMC Cancer (2017)
-
Syndromic gastrointestinal stromal tumors
Hereditary Cancer in Clinical Practice (2016)
-
Current and Future Treatments for Malignant Pheochromocytoma and Sympathetic Paraganglioma
Current Oncology Reports (2013)
-
Carney Stratakis Syndrome in a Patient with SDHD Mutation
Endocrine Pathology (2012)
-
Novel germline SDHD mutation: diagnosis and implications to the patient
Familial Cancer (2011)